2017 - Ongoing

Client
World Health Organisation (WHO)

Market Information for Access to Vaccine (MI4A) Initiative

Since 2017, MMGH has provided ongoing support to the WHO Expanded Program on Immunisation’s MI4A initiative aimed at enhancing countries’ access to safe, effective, quality, and affordable vaccines. MMGH consults with manufacturers, defines the methodological aspects of the studies, evaluates current and future supply, identifies bottlenecks on the supply-demand balance, and proposes mitigating measures. To-date, the project has produced market studies for Bacillus Calmette-Guerin (BCG), Human papillomavirus (HPV), Meningococcal meningitis, Diphtheria & Tetanus-containing, Measles-containing, Pneumococcal, Typhoid and Rabies vaccines. In 2021, the project has focused on evaluating the risks and impacts of the SARS-Cov-2 pandemic and COVID-19 vaccine production to the access and availability of vaccines for routine immunisation.

Related Publication(s)

2018

Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance...

Author
246

Abstract

Over the past decade, several countries across all regions, income groups and procurement methods have been unable to secure sufficient BCG vaccine supply. While the frequency of stock-outs has remained rather stable, duration increased in 2014–2015 due to manufacturing issues...

2019

Global market study: BCG vaccine...

Author
265, 246

Abstract

For the next five years, the annual BCG vaccine supply is estimated to be ~2X greater than the annual forecasted demand, which is an increase from the 2017 analysis and is driven by one supplier returning to the market and...

2018

Global market update: BCG vaccine...

Author
246, 265

Abstract

In response to repeated calls from WHO Member States, WHO launched the Market Information for Access to Vaccines (MI4A) initiative to enhance vaccine market transparency and understand global vaccine market dynamics. This report provides a snapshot of the global vaccine...

2019

Global market study: Diphtheria and Tetanus containing vaccines...

Author
265, 246

Abstract

WHO recommends that all countries: 1) follow a life course of 6 doses of Diphtheria and Tetanus (D&T)-containing vaccines and 2) replace TT with Td vaccine. As of January 2019, 108 countries have not implemented one or both of these...

2019

Global market study: HPV vaccines...

Author
265, 246

Abstract

Twelve years after the first HPV vaccine registration, less than half of WHO Member States have introduced HPV vaccine into the routine national immunisation schedule. Introductions are lowest in Gavi countries and non-Gavi, non-PAHO middle- income countries (MICs). Supply is...

2019

Global market study: Meningococcal meningitis vaccines...

Author
265, 246

Abstract

The meningococcal vaccine market is diverse and complex, with regional variations in serogroup distribution, significant use outside of routine immunisation, and 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y). Discontinued production of...

2020

Global market study: Pneumococcal conjugate (PCV) and polysaccharide (PPV) vaccines...

Author
265, 246

Abstract

National introduction of PCV in infant routine immunisation in 42 countries – including large ones like India, China and Indonesia – will trigger an increase of demand in excess of 60 million doses over the next ten years. Supply of...

2020

Global market study: Typhoid Vaccines...

Author
265, 246

Abstract

ViPS and Ty21a markets are largely focused on the private sector and travellers markets. Given the product characteristics of TCV, it is anticipated that demand for these markets will decrease and the manufacturers will exit the market in the mid-...